AstraZeneca Proclaims Promising Long-Acting COVID-19 Antibody
Results For Evusheld Upgrade Due In H2 2023
Executive Summary
AstraZeneca vaccine chief Mark Esser is excited about the first in vitro data on AZD3152 which show that the antibody neutralizes all known variants, from Wuhan to Omicron XBB.1.5.